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a b s t r a c t
Liquid chromatography tandemmass spectrometry (LC/MS/MS) is replacing classicalmethods for steroid
hormone analysis. It requires small sample volumes and has given rise to improved speciﬁcity and short
analysis times. Its growth has been fueled by criticism of the validity of steroid analysis by older tech-
niques, testosterone measurements being a prime example. While this approach is the gold-standard
for measurement of individual steroids, and panels of such compounds, LC/MS/MS is of limited use in
deﬁning novel metabolomes. GC/MS, in contrast, is unsuited to rapid high-sensitivity analysis of speciﬁc
compounds, but remains the most powerful discovery tool for deﬁning steroid disorder metabolomes.
Since the 1930s almost all inborn errors in steroidogenesis have been ﬁrst deﬁned through their urinary
steroid excretion. In the last 30 years, this has been exclusively carried out byGC/MS and has deﬁned con-
ditions such as AME syndrome, glucocorticoid remediable aldosteronism (GRA) and Smith–Lemli–Opitz
syndrome. Our recent foci have been on P450 oxidoreductase deﬁciency (ORD) and apparent cortisone
reductase deﬁciency (ACRD).
In contrast to LC/MS/MS methodology, a particular beneﬁt of GC/MS is its non-selective nature; a
scanned run will contain every steroid excreted, providing an integrated picture of an individual’s
metabolome. The “Achilles heel” of clinical GC/MS proﬁling may be data presentation. There is lack
of familiarity with the multiple hormone metabolites excreted and diagnostic data are difﬁcult for
endocrinologists to comprehend. While several conditions are deﬁned by the absolute concentration
of steroid metabolites, many are readily diagnosed by ratios between steroid metabolites (precursor
 metabolite/product metabolite). Our work has led us to develop a simpliﬁed graphical representation of
quantitative urinary steroid hormone proﬁles and diagnostic ratios.
© 2010 Elsevier Ltd. 
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. Introduction
Urinary steroid proﬁling has been a critical part of the diag-
osis of disorders of steroid hormone synthesis and metabolism
ince the 1960s, ﬁrst by thin layer chromatography, followed by
as chromatography and gas chromatography–mass spectrome-
ry (GC/MS). However, immunoassays and related techniques have
een widely used for quantiﬁcation of plasma steroid hormones
n routine diagnostic processes for established conditions. While
uch techniques have been central to our ability to diagnose clini-
al disorders, data are frequently compromised since the problem
f cross-reactivity has never been completely solved for several
nalytes, thus impacting speciﬁcity. Another problem commonly
ccurs when low concentrations of hormones are quantiﬁed, as in
ediatric patients or postmenopausal women. Furthermore, large
nterassay variability exists even for common measurements such
s testosterone, estradiol, and progesterone [1]. These difference
ig. 1. Synthesis and metabolism of hormonal steroids. This ﬁgure illustrates the format
cript are steroid hormones and precursors; those in italics are urinary metabolites of t
he cofactor (“facilitator”) enzymes in ovals. The pale blue area contains common interm
ineralocorticoids; the orange, glucocorticoids; dark blue, androgens and pink, estrogen
eductase (ADR) and adrenodoxin (Adx) CYP11A1, CYP11B1, CYP11B2, are marked with a l
xidoreductase (POR), CYP17A1, CYP21A2, CYP19A1, are marked by circled POR. The 17,2
5 indicated by a circled b5. Similarly, hexose-6-phosphate dehydrogenase (H6PDH) is
ydroxylation of 17OHP to 21-deoxycortisol in 21-hydroxylase deﬁciency. The conversi
KR1C3 (HSD17B5) in the adrenal. StAR, steroidogenic acute regulatory protein; CYP11A
ype 2; CYP17A1, 17-hydroxylase; CYP21A2, 21-hydroxylase; CYP11B1, 11-hydroxyla
YP19A1, P450 aromatase; SRD5A2, 5-reductase type 2; SULT2A1, sulfotransferase 2A1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 504
have been signiﬁcantly lowered between laboratories using liquid
chromatography tandem mass spectrometry (LC/MS/MS) [1]. The
latest generation of GC/MS and LC/MS/MS techniques are superior
to immunoassays regarding speciﬁcity and limits of quantiﬁcation,
providing a good linearity even down to low concentrations. Since
LC/MS/MS high-sensitivity and high-speciﬁcity measurement can
be allied with high throughput, many diagnostic laboratories are
adopting this new technology. While LC/MS/MS will be the main-
stream technology in steroid hormone analysis in the near future, it
is notwithout its limitations, with one drawback being that analyte
measurements are always targeted, even when panels of steroids
are measured in single runs.
The targeted analytes for radioimmunoassays (RIAs) or tandem
MS analysis are selected steroid hormones and their precursors
illustrated in the steroidbiosyntheticpathway (Fig. 1, abbreviations
listed in Table 1). Historically the analytes requested for patient
studies have been kept to a minimum because of cost and lack
ion of the major hormone classes from cholesterol. Steroid names in conventional
he aforementioned. The major transformative enzymes are in rectangular boxes,
ediate steps; the yellow preliminary steps in glucocorticoid synthesis; the green
s. Mitochondrial CYP type I enzymes requiring electron transfer via adrenodoxin
abelled box ADR/Adx. Microsomal CYP type II enzymes receive electrons from P450
0-lyase reaction catalyzed by CYP17A1 requires in addition to POR also cytochrome
the cofactor-generating enzyme for 11-HSD1. The asterisk (*) indicates the 11-
on of androstenedione to testosterone is catalyzed by HSD17B3 in the gonad and
1, P450 side-chain cleavage enzyme; HSD3B2, 3-hydroxysteroid dehydrogenase
se; CYP11B2, aldosterone synthase; HSD17B, 17-hydroxysteroid dehydrogenase;
; PAPPS2, 3′-phosphoadenosine 5′-phosphosulfate synthase 2.
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Table 1
Abbreviations of steroid hormone metabolites.
Abbreviation Full trivial name Metabolite of
An Androsterone Androstenedione, testosterone, 5-dihydrotestosterone, DHEA
Et Etiocholanolone Testosterone, DHEA
DHEA (and sulfate) Dehydroepiandrosterone Dehydroepiandrosterone
11-OH-An 11-Hydroxy-androsterone 11-OH-androstenedione, cortisol
11-OH-Et 11-Hydroxy-etiocholanolone Cortisol
11-OXO-Et 11-Oxo-etiocholanolone Cortisol
16-DHEA 16-OH-DHEA Dehydroepiandrosterone, Dehydroepiandrosterone-sulfate
PDa Pregnanediola Progesterone, 11-deoxycorticosterone
5PD Pregnenediol Pregnenolone
Pregnadienolb Pregnadienol Pregnenolone (pregnenediol)
17HP 17-OH-pregnanolone 17-OH-progesterone
3517HP 35-17-OH-pregnanolone 17-OH-progesterone and other fetal origin
PT Pregnanetriol 17-OH-progesterone
5PT 5-Pregnenetriol 17-OH-pregnenolone
PTONE Pregnanetriolone 21-Deoxycortisol
THDOC Tetrahydrodeoxycorticosterone 11-Deoxycorticosterone
5THDOC 5-Tetrahydrodeoxycorticosterone 11-Deoxycorticosterone
THS Tetrahydro-11-deoxycortisol 11-Deoxycortisol
THA Tetrahydro-11-dehydrocorticosterone Corticosterone
5THA 5-Tetra-11-dehydrocorticosterone Corticosterone
THB Tetrahydrocorticosterone Corticosterone
5THB 5-Tetrahydrocorticosterone Corticosterone
THALDO Tetrahydroaldosterone Aldosterone
THE Tetrahydrocortisone Cortisol, cortisone
THF Tetrahydrocortisol Cortisol
5THF 5-Tetrahydrocortisol Cortisol
-Cortolone -Cortolone Cortisol, cortisone
-Cortolone -Cortolone Cortisol, cortisone
-Cortol -Cortol Cortisol
-Cortol -Cortol Cortisol
6-OH-cortisol 6-OH-cortisol Cortisol
o
t
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ta When not speciﬁed the A-ring conﬁguration is 3,5- in all abbreviations.
b A chemical artifact formed exclusively from 5PD (pregnenediol) disulfate.
f availability of tests for less common analytes. However, with
he advent of tandem MS panels steroid hormone proﬁles will be
outinely measured.
An alternative analytical technique available for 40 years is
as chromatography mass spectrometry (GC/MS). GC/MS is used
o analyse the metabolites of steroid hormones and their precur-
ors (steroid metabolite abbreviations in italic script in Fig. 1).
his technique can readily be utilized in comprehensive (full
can) and targeted (selected ion) mode. A “scanned” GC/MS run
ontains all steroids excreted and the data set can be searched
or any required analyte even years after the analysis. For the
ast 70 years almost all disorders of steroid hormone biosyn-
hesis and metabolism have been characterized and ﬁrst named
ollowingurine steroid analysis. Themost recentlydescribedexam-
les have had their steroid phenotype established using GC/MS,
mphasizing the diagnostic power and discovery potential of this
echnique.
Table 2
Comparison of the performance of GC/MS and LC/MS/MS for steroid analy
Task GC/MS
Ease of sample prep Time-consu
Derivatization Necessary
Automation Injection on
Speed of analysis Long
Chromatographic resolution Excellent
Steroid conjugate detection No
Epimer separation Good
Speciﬁcity Excellent
Sensitivity 3-oxo-4-ene steroids Moderate
Sensitivity 3-hydroxysteroids Good
Non-targeted steroid proﬁles Good
Non-polar compounds (sterols) GoodMany believe tandem MS sounds the death knell of GC/MS.
In contrast, while we believe that LC/MS/MS of serum steroid
hormones will dominate clinical analysis, GC/MS of excreted
metabolites will retain an important role. The techniques will be
complementary rather than competitive. LC/MS/MS will be the
method of choice to determine targeted steroids and proﬁles of
such, whereas GC/MS will probably remain the pre-eminent tool
for novel steroid metabolome discovery. GC/MS has also an addi-
tional role as a non-invasive and integrative method for known
disorders of steroidogenesis, particularly useful in young infants.
One of the biggest drawbacks to the adoption of GC/MSmethod-
ology in clinical steroidology has been the presentation of data in a
simple form, interpretable by endocrinologists unfamiliar with the
intricacies of steroid metabolism. We present an improved visual
presentation of GC/MS data to make these complex metabolomes
user-friendly and easier to understand for clinicians and scientists.
To illustrate this, we provide two recent examples of the use of
sis.
HPLC/MS
ming Minimal
Generally not needed
ly All stages.
Short
Poor (short run time)
Good
More difﬁcult
Excellent
Excellent
Poor
Poor
Poor, derivatization necessary
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mig. 2. Proposed “back-door” pathway to androgens in ORD pregnancy. Proposed p
nd androsterone.
C/MS to biochemically deﬁne novel entities in steroid hormone
iology.
. Methodology utilized
The methods of sample work-up for GC/MS analysis (conjugate
ydrolysis, extraction and derivatization) have been published in
everal papers [2,3]. While the methodologies have been improved
ver the years the original conditions developed and proven for
xtraction, hydrolysis and derivatization documented in Shackle-
on’s review from 1986 [4] essentially hold true. A recent paper
5] is very comprehensive as it details the selected-ion-monitoring
ethod (SIM) for diagnosis of most steroid biosynthetic andtion of dihydrotestosterone via 5-reduced metabolites 5-17-OH-pregnanolone
metabolic disorders. We commonly target about 40 steroids for
SIM analysis which cover all disorders of steroid synthesis and
metabolism. However, we always have a back-up scanned run in
case other measurements are desired in the future.
3. Comparison of GC/MS and LC/MS/MS for steroid analysis
A comparison of the technical features of both techniques is
summarized in Table 2. LC/MS/MS has the advantage of rapid spe-
ciﬁc analysis of a limited number of compounds at high sensitivity
and it is relatively easily automated. Hydrolysis of conjugates and
chemical derivatization are not required. Thus, LC/MS/MS is ideally
suited to routine diagnostics. Structural characterization of novel
500 N. Krone et al. / Journal of Steroid Biochemistry & Molecular Biology 121 (2010) 496–504
Table 3
When GC/MS is preferred technique in steroid analysis.
Clinical practice
1. First-pass investigation of challenging patients- an integrated
picture of synthesis and metabolism obtained
2. More reliable diagnosis of metabolism versus synthesis disorders,
e.g. AME syndrome, ACRD, 5-reductase deﬁciency
3. Deﬁning new metabolomes of biosynthetic and metabolic disorders
4. Less invasive sampling in pediatrics
5. Prenatal diagnosis of steroid biosynthetic disorders
Basic science applications
1. Study of developmentally related synthesis and metabolism
changes. Example deﬁning pregnancy “back-door” pathway to active
androgens in ORD.
2. Mouse models of human disorders, deﬁning the mouse metabolome
and documenting changes in genetically altered animals
Doping in sports
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ORD revealed severely decreased estriol synthesis. Maternal signs1. Identiﬁcation of previously unseen designer drugs and metabolites,
e.g. tetrahydrogestrinone
2. Stable carbon isotope ratio measurements (in the form of GC/C/MS)
teroids is difﬁcult by this technique and “scanning” runs of ill-
eﬁned metabolomes are difﬁcult to obtain and interpret.
GC/MS has the advantage over LC/MS/MS of inherently better
hromatographic resolution. LC column resolution has improved
reatly recently through the use of small particle size packings
UPLC, ultraperformance LC) but is still compromised due to the
eed for short run times. GC/MS commonly relies on derivatiza-
ion of steroids using methyloxime-trimethylsilyl ether (MO-TMS)
ormation, which is disadvantageous in being labor intensive, but
ermits the ready characterization of structures through rela-
ively easy determination of the number of C O and C–OH groups.
urthermore, derivatization usually directs the MS fragmentation
nd a large body of knowledge is available on genesis of spe-
iﬁc ions generated within GC/MS analysis. This allows for easier
etermination of placement of functional groups on the steroid
olecule [3]. GC/MS analysis is the superior technology to sep-
rate epimeric steroids, so is particularly useful in disorders of
etabolism such as 17-hydroxysteroid dehydrogenase type 3
eﬁciency, 5-reductase type 2 deﬁciency, apparent mineralocor-
icoid excess (AME) and apparent cortisone reductase deﬁciency
ACRD).
Using the GC/MS in scan mode allows for non-targeted steroid
roﬁling and for the discovery of novel compounds, metabolomes
nd pathways of synthesis and metabolism. Scanned data can be
tored indeﬁnitely for future revisiting. These advantagesmake the
echnique as a “discovery tool”. Table 3 lists several of the circum-
tances in which GC/MS analysis prevails. Finally, while sufﬁcient
peciﬁcity in steroid identiﬁcation canbeachievedbya single-stage
e.g. single quadrupole) mass spectrometer, GC allied to tandem
ass spectrometers (bench top GC/MS/MS ion-trap instruments)
ave been long available. In certain circumstances, particularly
hen small amounts of a targeted analyte are to be measured in
he presence of high background, these instruments are invaluable.
his is discussed in detail in a paper in this volume [6].
. Speciﬁc advantages of GC/MS urine proﬁling in pediatrics
The sample volume required for steroid hormone analysis
mploying LC/MS/MS has been signiﬁcantly reduced compared
ith immunoassays and steroid hormone proﬁles have been suc-
essfully established as diagnostic tests to differentiate between
efects in steroidogenesis. This technology has been proven suc-
essful as second-tier or conﬁrmation tests in neonatal congenital
drenal hyperplasia (CAH) screening programs [7,8] relying on
lood spot analysis. However, if used as a conﬁrmation test or as aFig. 3. Diagnostic ratios of ACRD. The diagnostic ratios are of major 11-oxo over
11-hydroxy compounds. The normal means, 5th and 95th centiles are given. The
square symbols are the ACRD patient results.
diagnostic test in patients with later manifestation, one has to bear
in mind that this methodology relies on blood sampling, which in
a pediatric setting is often traumatizing for patients and parents.
Furthermore, blood sampling reﬂects just a single time point rather
than an integrated picture of the steroid metabolome over a longer
time span as obtained by GC/MS urine steroid analysis. Applying
speciﬁc diagnostic metabolite ratios allows for the straightforward
diagnosis of conditions of adrenal origin and other disorders of sex
development without needing timed sample collection [2,3,9,10].
4.1. GC/MS as a discovery tool for novel metabolomes and
creating novel hypotheses
4.1.1. The example of P450 oxidoreductase deﬁciency
The metabolome of what is now termed P450 oxidoreduc-
tase deﬁciency (ORD) was accurately described long ago by
thin layer chromatography and GC/MS urine proﬁle analysis
and was named combined 17-hydroxylase/21-hydroxylase deﬁ-
ciency [11–13]. Patients with ORD present with a pathognomonic
urine steroid proﬁle showing increased metabolites typically
seen in 21-hydroxylase deﬁciency, such as pregnanetriol, 17-OH-
pregnanolone and pregnanetriolone (17OHP and 21-deoxycortisol
metabolites) increased excretion of mineralocorticoid precursors
(corticosterone metabolites) and decreased excretion of active
androgen metabolites [13]. Interestingly, over the last 30 years
there have been multiple publications of misdiagnoses of this con-
dition, usually as variants of 17-hydroxylase deﬁciency, because
insufﬁcient plasma analytes were measured by conventional tech-
niques to uncover both the apparent 17- and 21-hydroxylase
deﬁciencies [13]. In2004, the true causeof this conditionwasestab-
lished as deﬁciency of P450 oxidoreductase, the enzyme essential
forproviding theelectrons requiredbymanysteroidhydroxylases–
cytochrome P450 type II enzymes [14,15]. A further paradox is that
46,XX babies are occasionally bornwith virilized external genitalia,
and 46,XY individuals are frequently born with undermasculinized
external genitalia. GC/MS provided an ideal technique for diagno-
sis of the condition as all metabolites of both corticosterone and
17OHP could be analyzed in a single chromatogram [16].
4.1.2. The role of GC/MS in uncovering the cause of genital
ambiguity in ORD
Longitudinal monitoring of pregnancies carrying fetuses withof virilization by the 23rd week of gestation were also reported,
which is often associated with aromatase deﬁciency. However,
pathognomonic urinary metabolite analytes for diagnosis of aro-
matase deﬁciency were not signiﬁcantly increased. An increased
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Fig. 4. Report of urinary steroid quantitation as g/24h. The upper panel shows the normal excretion of metabolites in adults. The color-coding is the same as described
in Fig. 1. Mean values, 5th and 95th percentile and given. The middle panel shows results quantiﬁed in the 24-h urine of a patient, with individual measurement results
illustrated by black dots. This case was diagnosed as ORD because of the high excretion of metabolites of pregnenolone (highlighted in light blue) and progesterone (yellow)
with concurrent elevation of corticosterone pathwaymetabolites (green). The lower panel shows results for an ACRDpatient. Note the high excretion of androgenmetabolites
and the high excretion of cortisol metabolites containing an 11-carbonyl (e.g. THE, cortolones).
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Table 4
Diagnostic ratios for differential diagnosis of inborn errors of steroidogenesis and steroid metabolism.
Enzyme defect (Gene) Diagnostic ratio
21-Hydroxylase deﬁciency (CYP21A2) 17HP/(THE+THF+5THF)
PT/(THE+THF+5THF)
PTONE/(THE+THF+5THF
11-Hydroxylase deﬁciency (CYP11B1) THS/(THE+THF+5THF)
17-Hydroxylase deﬁciency (CYP17A1) (THA+5THA+THB+5THB)/(THE+THF+5THF)
(THA+5THA+THB+5THB)/(An+Et)
3-Hydroxysteroid dehydrogenase deﬁciency (HSD3B2) DHEA/(THE+THF+5THF)
5PT/(THE+THF+5THF)
P450 oxidoreductase deﬁciency (ORD) (POR) (17HP+PT)/(An+Et)
(17HP+PT)/(THE+THF+5THF)
PD/(THE+THF+5THF)
5PD/(THE+THF+5THF)
(THA+5THA+THB+5THB/(THE+THF+5THF)
Apparent mineralocorticoid excess (AME) (HSD11B2) F/E
(THF+5THF)/THE
Cortols/cortolones
(F +E)/(THF+5THF+THE)
Apparent cortisone reductase deﬁciency (ACRD) (H6PDH) THE/(THF+5THF)
Cortolones/cortols
5-Reductase deﬁciency (SRD5A2) Et/An
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p17-Hydroxysteroid dehydrogenase deﬁciency (HSD17B3)
xcretion of the normally minor metabolite 5-pregnane-3,
0-diol (epiallopregnanediol), an epimer of the main proges-
erone metabolite pregnanediol (5-pregnane-3,20-diol), was
etected. Epiallopregnanediol is largely thematernalurinaryexcre-
ion product of fetal 5-pregnene-3,20-diol, itself the principal
etabolite of pregnenolone. Since pregnenolone is the precursor
f all hormonal steroids, including estriol, this suggested an early
lock in the estriol biosynthesis pathway in the fetal adrenal [17].
emarkably, a rapid increase in the androgen metabolite andros-
erone was noted in the ﬁrst trimester with a peak at around
0 weeks. This suggested increased synthesis of testosterone and
-dihydrotestosterone as a probable cause of the maternal vir-
lization. The clinical picture, together with biochemical evidence
ained by urine steroid GC/MS analysis, led to the hypothesis of
he existence of an alternative “back-door” pathway of andro-
en synthesis [15] relying on intermediates similar to a pathway
escribed in the testis of the Tammar Wallaby pouch young [18].
he existence of this “back-door” pathway to androgen synthesis
as further supported by analysis of the urine steroid metabolites
y GC/MS of additional ORD patients [19] (Fig. 2).
This example highlights the power of GC/MS analysis to char-
cterize new disease entities; to deﬁne developmental changes
uring pregnancy, and to generate novel hypothesis such as the
xistence of the alternative “back-door” pathway to active andro-
ens. These studies would have been challenging for tandem
C/MS/MS. GC/MS of urinemetabolites clearly allows prenatal test-
ng for ORD, as it does for Smith–Lemli–Opitz syndrome (SLOS)
20] and steroid sulfatase deﬁciency [21]. No LC/MS/MS meth-
ds utilizing maternal serum steroids are yet available for these
isorders.
.2. The example of apparent cortisone reductase deﬁciency
hexose-6-phosphate dehydrogenase deﬁciency)As for ORD the history of this disorder goes back 25 years when
heunusualmetabolomewasﬁrst indicated [22–24]. This condition
as described in two sisters with hirsutism and increased cortisol
roduction without signs and symptoms of Cushing syndrome. TheTHB/5THB
THF/5THF
(An+Et)/(THE+THF+5THF)
patients presentedwith increased excretion of tetrahydrocortisone
(THE) and related 11-oxo-steroids relative to 11-hydroxylated
compounds, resulting in the term “apparent cortisone reduc-
tase deﬁciency” (ACRD) being applied to the condition. Several
other patients have been described in the last few years and
exhaustive studies have shown that defects in hexose-6-phosphate
dehydrogenase resulting in a lack of reduced nicotinamide ade-
nine dinucleotide phosphate underlie the condition. GC/MS was
essential in diagnosing these patients as well as proving the deﬁ-
ciency through studying the metabolome of the mouse model
of the condition [25]. The increased and irreversible conversion
of cortisol to cortisone presumably protects against the negative
effects of hypercortisolism in this condition. Hyperandrogenism
is secondary to increased cortisol clearance and the main clinical
manifestation of ACRD. Ratios of cortisol to cortisone metabolites
(THE/[THF+5THF], cortolones/cortols) simplify the diagnosis of
this condition (Fig. 3).
It would have been almost impossible to deﬁne this disorder
and elucidate the pathophysiology of ACRD without GC/MS of uri-
nary metabolites. This condition also illustrates the importance of
metabolite assays in certain instances. The measurement of urinary
cortisol and cortisone using LC/MS/MS has been described [26].
However, applying this diagnostic technology would have most
likely failed to establish the diagnosis of ACRD, because in patients,
the ratio of unmetabolized cortisol to cortisone is normal; thusdoes
not showevidenceof apparent 11HSDdeﬁciency. ACRD is another
keyexampleof thepowerofurine steroidanalysisGC/MSemployed
as a discovery tool in undeﬁned disease entities.
5. Improving the presentation of GC/MS data
A major shortcoming of clinical GC/MS urine steroid proﬁling
is in data presentation. Our current standard SIM analysis includes
more than 30 steroid hormone metabolites, most of which are only
familiar names and structures to the expert. Tabulating only the
quantiﬁed amounts of steroid metabolites can be confusing and
elusive. While naming and measuring these metabolites remains
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sing the designated ratios that the diagnosis can be accurately given. Only the ORD
mportant, improvement in the visual presentationof datahas been
ade.
In steroid proﬁling, there are two types of data in common use:
1) quantitative data of individual metabolites and (2) diagnostic
atios of precursor metabolites to product metabolites.
.1. Quantitative data
Quantitative data on excretion of individual steroids is ideal
ut requires accurate 24h sampling. Most steroid disorders can be
dentiﬁed from “spot” or random samples but in certain cases, for
xamplewhen evaluating aldosterone synthesis, accurate quantiﬁ-
ation is essential.
The pathway to steroid hormone production is commonly
ivided into the synthesis ofmineralocorticoid, glucocorticoids and
ex steroids (Fig. 1). We have added two groups to this classiﬁca-
ion; ‘androgenprecursors’ includes the5-steroidspregnenolone,
7OH-pregenenolone, DHEA and the4-steroids androstenedione
nd their metabolites as this represent the main pathway to
ctive androgens. The second additional group is of ‘glucocorti-
oid precursors’, which consists of the 4-steroids progesterone,
7OH-progesterone and 21-deoxycortisol and their metabolitesompared to normative data appropriate for several forms of CAH. It is clear that by
s are all abnormal.
(Fig. 1).Wehaveusedournormal controls todevelopnormal ranges
in groupings for metabolites of androgens, androgen precursors,
mineralocorticoids and precursors, glucocorticoid precursors and
glucocorticoids (Fig. 4A). The GC/MS proﬁle of an individual patient
is plotted for each determined parameter versus the normal refer-
ence population. Such proﬁles allow for an immediate overview on
a rather complex constellation. As exempliﬁed in Fig. 4B, it is obvi-
ous that the individual has a condition with androgen deﬁciency
involvingandrogenprecursors, in combinationwith increasedmin-
eralocorticoid precursors and increased amounts of glucocorticoid
precursors, but normal glucocorticoids under non-stress condition,
the hallmarks of ORD.
5.2. Diagnostic ratios
Most hormonal imbalances caused by enzyme deﬁciencies or
“blocks” cause depletion of a steroid product and build-up of the
upstream precursors. Thus, a ratio of metabolites of the product
to metabolites of the product should indicate if there is such a
block. Such ratios have been used for years and are available for
most steroid disorders (Table 4). Although this approach simpli-
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es data presentation and does not require timed samples, most
linical “end users” are often alienated by such numerical data pre-
entation and only an exclusive audience with a special interest in
teroid hormone metabolism gets beneﬁt from such results with
thers relying on result interpretation by a few experts. To sim-
lify this problem and make this important information available
o a broader clinical audience, we have developed disease spe-
iﬁc graphics based on substrate/product ratios. Certainly some
nowledgeonsteroidmetabolites is required, butgraphicalpresen-
ationofurine steroidproﬁles asquantitative reports versusnormal
ontrols and diagnostic “precursormetabolite/productmetabolite”
atios will allow for wider use of these data sets.
The CAH panel contains three speciﬁc ratios for 21-hydroxylase
eﬁciency, one for 11-hydroxylase deﬁciency, two for 17-
ydroxylase deﬁciency and3-HSD type 2 deﬁciency each, andﬁve
or ORD (Fig. 5). Applying these representations leads to imme-
iate differentiation between different forms of known errors
n steroidogenesis. Patients’ proﬁles and ratio combinations not
tting these established diagnostic criteria, thus excluding estab-
ished conditions, can be reanalyzed by various techniques to
lucidate novel underlying defects.
. Conclusions
With the advent of high throughput LC/MS/MS most classi-
al steroid analytic techniques can be replaced by measurement
f hormones and precursors; in particular for more common
onditions and well-known analytes. Accurate values are gener-
lly being obtained for the ﬁrst time, particularly in female and
ediatric patients with low concentrations of androgens and estro-
ens although work is still necessary in improving reproducibility
etween laboratories. In spite of this advance, GC/MS will continu-
usly play an active role in studying rare and undeﬁned conditions
nd retains its place as the pre-eminent discovery tool for deﬁning
ew and aberrant metabolic pathways and for ﬁrst-time charac-
erization of unknown steroids. It remains the best technique for
tudying “metabolic” in contrast to “biosynthetic” disorders (e.g.
-reductase deﬁciency, AME, ACRD), and is good in pediatric
ituations when it is desirable to minimize blood sampling. The
echnique is still at the core of methods for prenatal diagnosis of
teroid disorders by analysis of maternal urine or amniotic ﬂuid.
hus, we regard both mass spectrometric techniques as comple-
entary rather than competing technologies.
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